Priya Vishnubhotla, MD
Hematology & Oncology · Conyers, GANPI 1952393803
Payments from drug & device makers
Across 55 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$186
- Daiichi Sankyo Inc.$158
- Pfizer$155
- Merck$124
- Gilead$110
- AbbVie$101
- plus $503 from 12 others
What the payments were for
- Food & beverage$1,23492%
- Education$1038%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $186 |
| Daiichi Sankyo Inc. | 6 | $158 |
| Pfizer | 8 | $155 |
| Merck | 5 | $124 |
| Gilead | 4 | $110 |
| AbbVie | 4 | $101 |
| Sanofi | 3 | $78 |
| Novartis | 3 | $77 |
| Johnson & Johnson | 3 | $76 |
| Stemline Therapeutics Inc. | 3 | $67 |
| Sanofi-aventis U.S. LLC | 1 | $42 |
| Sobi, Inc | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $26 |
| Legend Biotech USA Inc. | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| GSK | 1 | $17 |
How this compares
$1,337 in reported general payments places this provider in the 25th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 19 | $1,681 |
| Ondansetron Hcl | 14 | $606 |
| Tamoxifen Citrate | 22 | $437 |
| Letrozole | 27 | $323 |
| Anastrozole | 15 | $125 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Conyers
- Chandar BhimaniConyers$483K
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.